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Marrow-infiltrating 
Lymphocytes – role in Biology and 
cancer therapy
Ivan Borrello* and Kimberly A. Noonan
Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
The past several years have witnessed the acceptance of immunotherapy into the 
mainstream of therapies for patients with cancer. This has been driven by the clinical 
successes of antibodies to the checkpoint inhibitors, CTLA-4 and PD-1, capable of 
imparting long-term remissions in several solid tumors as well as Hodgkin’s lymphoma 
(1) and the therapeutic successes of adoptive T-cell transfer with chimeric antigen 
receptors (2) or modified T-cell receptors (3) that have mostly utilized peripheral T-cells. 
One emerging area of therapeutic T cell intervention has been the utilization of marrow- 
infiltrating lymphocytes (MILs) – a novel form of adoptive T-cell therapy. This approach 
was initially developed to increase the likelihood of a precursor T-cell population with an 
enhanced tumor specificity in bone marrow (BM)-derived malignancies. However, the 
unique attributes of BM T-cells and their interaction with their microenvironment provide 
significant rationale to utilize these cells therapeutically in diseases that extend beyond 
hematologic malignancies.
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iNtrODUctiON
Most adoptive T-cell therapy has utilized the circulating pool of peripheral blood lymphocytes 
(PBLs). This is likely due to the relative ease of obtaining these cells through large volume 
pheresis. An alternative approach pioneered by Dr. Rosenberg and colleagues at the National 
Cancer Institute has focused on the use of tumor infiltrating lymphocytes (TILs) in patients with 
metastatic melanoma (4). The rationale for TILs is that tumor-specific T-cells are more likely 
to be found in proximity of the tumor. This has proven to be true, and several clinical studies 
have demonstrated appreciable tumor specificity with measurable antitumor efficacy. However, 
limitations exist with the TIL approach. First, in contrast to PBLs, TILs are not present in all 
individuals, they require a surgical procedure for harvesting, and the expansion protocols are 
often both lengthy and costly.
In hematologic malignancies, MILs likely offer the same benefits of TILs. Being obtained from 
the tumor microenvironment in myeloma as well as several other hematologic malignancies, these 
cells demonstrate heightened tumor specificity upon activation and expansion (5). However, the 
unique immunologic properties of bone marrow (BM) impart essential properties that could pos-
sibly make them an even better source of T-cells for adoptive therapy approaches than their PBL 
counterparts.
FiGUre 1 | cXcr4 expression in activated PBLs compared to activated MiLs. The T cells were activated with anti-CD3/CD28 beads, and CXCR4 
expression was then assessed by flow cytometry.
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rAtiONALe FOr Use OF MiLs iN 
ADOPtive t ceLL tHerAPY
Effective adoptive T-cell therapy requires T-cells to possess impor-
tant attributes. At a minimum, they must (1) possess endogenous 
tumor specificity, (2) be capable of trafficking to the tumor site 
upon infusion, (3) kill the tumor upon encounter, and (4) persist 
over time. MILs possess these properties in large part because of 
the unique immune environment present within the BM.
T-cells compose only 3–8% of the population within the BM 
(6). However, the BM plays a critical role in priming naive T-cells 
(7), serving as a reservoir of antigen experienced CD8 memory 
T cells (8), and the site of homeostatic proliferation of both CD4 
and CD8 T-cells (9, 10). While the BM lacks the organized struc-
ture of the lymph node or spleen, it does provide an environment 
that supports appropriate T-cell development in the absence of 
the thymus (11) and is capable of forming lymphoid follicles 
which increase with inflammatory, autoimmune, or infectious 
states (12). Despite this immune function, the BM lacks lymphatic 
vessels and is vascularized only by blood vessels. The absence of 
lymphatic vessels likely enables the massive lymphocyte recircu-
lation that occurs daily. However, entrance of central memory 
TCM cells into the BM is a more tightly regulated process mediated 
by an interaction between L-, P-, and E-selectins, whereas arrest 
within the BM requires the VCAM-1/α4β1 pathway (13).
Stromal-derived factor-1/CXCL12 is highly expressed in the 
BM, and its cognate receptor, CXCR4, is upregulated on memory 
T cells by IL-15 and increases adhesion of TCM to the BM microves-
sels (13, 14). Furthermore, memory T-cells have higher expression 
of CXCR4 compared to naive T-cells as its expression appears to 
be affected by the presence of antigen and various cytokines (14). 
In myeloma, we have confirmed the expression of CXCR4 on 
MILs, whereas no detectable expression was appreciated on PBLs 
from the same patients (Figure 1) (5). Of note, expression was 
even greater following activation with anti-CD3/CD28 beads. In 
hematologic malignancies, this expression may provide impor-
tant advantages to MILs, such as maximizing trafficking of the 
T-cells to the tumor microenvironment and thus further increase 
their therapeutic benefit in adoptive T-cell therapy. In addition to 
the possibility that CXCR4 expression on MILs can increase their 
trafficking to the BM, its increased expression on memory T-cells 
also provides another justification for the use of MILs in adoptive 
T-cell therapy. Specifically, CXCR4 is also involved in promotion 
of CD8 TCM homeostatic proliferation and maintenance (15). CD8 
TCM imparts long-term memory and are essential to maximizing 
the overall efficacy of adoptive T-cell therapy (16). The combined 
increased expression of CXCR4 on memory T-cells, the increased 
trafficking of these T-cells in response to CXCL12 to the BM, and 
the subsequent enrichment of memory T cells within the BM all 
underscore the unique attributes of BM resident T-cells that make 
them an ideal source for adoptive T-cell therapeutic approaches. 
Trafficking to the tumor site, BM, and persistence over time are 
two important properties for T-cells in the treatment of hemato-
logic malignancies.
rOLe OF BM t ceLLs iN DiseAse 
reGULAtiON AND sYsteMic iMMUNitY
It is logical to assume that T-cells within a certain microenviron-
ment most likely possess an enhanced antigenic specificity for 
the cells residing within that organ. This is certainly the rationale 
behind the therapeutic use of TILs for the treatment of metastatic 
melanoma and other diseases, in which they have been employed 
and was the primary assumption used in the clinical development 
of MILs in multiple myeloma by our group. However, as outlined 
above, the BM represents a unique organ with several important 
immune attributes, which can be employed for therapeutic pur-
poses but can also contribute to the pathology of disease.
Hematologic Malignancies
The BM has been described as a reservoir for Tregs (17). 
Interestingly, this observation was made in healthy hosts, and 
our findings in myeloma demonstrated the opposite – more Tregs 
present in the peripheral blood than BM (18). This paradox was 
ultimately resolved by our demonstration that the large amounts 
of IL-6 produced by the myelomatous plasma cells in combina-
tion with TGF-β (as well as IL-1β and IL-21) were responsible 
for the skewing of CD4 away from a Treg phenotype toward a 
Th17 phenotype that was responsible for the activation of osteo-
clasts and the development of lytic bone lesions (18) as well as 
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the promotion of myeloma cell growth (19). Underscoring the 
importance of the immune composition of the BM, it was the 
extent of the Th17 phenotype of the BM (but not blood) T-cells 
and not the myeloma cell concentration that correlated to the 
extent of bone disease (18). Interestingly, activation of MILs with 
anti-CD3/CD28 resulted in a significant skewing toward a Th1 
phenotype and the addition of activated MILs to an osteoclast 
differentiation assay significantly reduced the outgrowth of 
osteoclasts (18). Taken together, these data not only provide 
an explanation for the immune-mediated contribution to lytic 
bone disease in myeloma but also suggest that an adoptive T cell 
approach, such as the utilization of Th1-skewed-activated MILs, 
could possibly also exert a benefit in terms of reducing bone 
disease.
viral responses
The role of the BM in serving as a reservoir of antigen- 
experienced T-cells is likely also mediated by the ability of the 
BM to effectively present antigen. In fact, it has been demon-
strated that differentiated dendritic cells (DCs) traffic and home 
to the BM where they then form stable antigen-dependent 
interactions with TCM (20). This interaction is likely one of 
the key mediators responsible for the maintenance of central 
memory in the BM. It is this attribute that also enables the BM 
to enrich for viral-specific memory T-cells. In a murine LCMV 
model, it was shown that no significant differences existed 
between the precursor frequency of LCMV-specific T-cells in 
the spleen and BM during the acute infection. Furthermore, 
long-term immunity was found in the BM and the spleen, and 
the adoptive transfer of BM from LCMV-infected mice was 
able to effectively protect against viral infection (21). Chronic 
viral infections, such as EBV, also demonstrate an increase in 
BM-specific T-cells to lytic antigens compared to the blood, 
which was independent of viral load (22). More importantly, 
that study showed a unique expression of homing receptors 
present on T cells obtained from the BM and not observed on T 
cells from other compartments.
solid tumors
In contrast to the two abovementioned conditions, in solid 
tumors (especially in the non-metastatic setting), it is unlikely 
that the BM will contain clinically detectable amounts of tumor. 
In breast cancer, tumor-specific T-cells have been identified in 
the BM to a greater extent than in the blood even in conditions in 
which tumor could not be detected by nested PCR (23). Similar 
results were also observed in melanoma and pancreatic cancer; 
although in the former, BM T-cell recognition was more com-
monly seen in patients with metastatic disease (24, 25). Based on 
these results, studies are currently ongoing examining the ability 
to utilize MILs as a therapeutic source of T cells in various solid 
tumors.
tHerAPeUtic rOLe OF MiLs
The abovementioned attributes underscore the uniqueness of the 
MILs as more than simply the TILs of hematologic malignancies. 
In fact, the demonstration by various groups that antigen-specific 
cells can be found even in the absence of known tumor or viral 
involvement of the BM provides the rationale for their therapeutic 
use in those disease settings as well.
Multiple Myeloma
Marrow-infiltrating lymphocytes do appear to possess many 
of the essential features that make them the ideal for adoptive 
T cell therapy and more specifically, for hematologic malignan-
cies. They have an endogenous antigenic specificity that is broad 
and targets antigens present on both the mature myelomatous 
plasma cells as well as their clonogenic precursors. In NOD/
SCID models, MILs have shown the ability to traffic to the BM, 
to persist with an activated phenotype, and to exert measurable 
antitumor activity (Figure  2). Our clinical data demonstrate 
a direct correlation between the ability to achieve a complete 
remission (CR), following the adoptive transfer of activated 
MILs and the presence of significant tumor-specific immunity 
to myeloma cell lysate (26). Studies to specifically determine 
the specific antigenic recognition are ongoing. However, the 
antigen-specific immunity appears to be both CD4- and CD8 
mediated.
These initial studies have led to the development of clinical tri-
als for myeloma in the autologous transplant setting. This involved 
the bedside harvest of 200 ml of BM, which was well tolerated with 
conscious sedation and from which MILs were then expanded in 
all patients. Of note, MILs were not isolated prior to activation 
but rather were expanded within the BM microenvironment 
because the presence of antigen during the T-cell expansion was 
shown to be critical to maintaining the tumor specificity of the 
MILs while subjected to the potent polyclonal expansion of CD3/
CD28 stimulation. However, underscoring the unique attribute of 
MILs, we have demonstrated that it is more than the presence of 
antigen during the expansion that is responsible for the antigenic 
specificity as PBLs expanded within the BM environment showed 
only a slight increase in the tumor specificity but significantly 
less could be achieved with MILs (5). In our clinical study, we 
observed an increase in the tumor specificity of the MILs in 
all patients. However, the magnitude of this specificity varied 
significantly post-expansion. Interestingly, a direct correlation 
existed between the extent of the tumor specificity obtained 
ex vivo and the clinical outcomes of the patients – higher tumor 
specificity and increased production of both IL-2 and IFNγ of the 
ex vivo product was associated with CRs (26). Several properties 
of MILs at baseline also seemed to correlate to clinical outcomes. 
Specifically, patients whose pre-expansion MILs had significant 
percentage of CD8 TCM and low spontaneous IFNγ production 
were more likely to achieve a CR to therapy. The demonstration of 
a direct correlation between the immune parameters of the T-cell 
product and clinical outcomes speaks to the endogenous tumor 
specificity of MILs.
Marrow-infiltrating lymphocytes were successfully adminis-
tered without the development of a cytokine release syndrome 
or significant lymphocytosis. This differs significantly from 
the infusion of activated PBL which, even when unmodified, 
demonstrated a significant lymphocytosis in vivo. The absence 
FiGUre 2 | Activated MiLs exert a potent antitumor MiLs. (A) NOD/SCID mice (10 mice per group) were challenged with the H929 myeloma cell line and 
followed until a detectable kappa light chain was present in the blood consistent with engraftment. The mice were challenged with either activated PBLs or activated 
MILs and followed for overall survival. (B) To determine the ability of these T cells to traffic and exert antimyeloma activity, the mice were sacrificed at the indicated 
time points. When mice that received aPBL died or conversely a mouse that received aMILs was sacked on D110 to analyze the BM was stained for either human 
CD3 cells or CD138+ myeloma. As shown, the mice that received MILs showed significant T cell trafficking to the BM and no detectable myeloma.
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of these effects, following the infusion of MILs, could be related 
to the infusion of a cell dose that was below the threshold for 
expansion or could reflect a different trafficking pattern of MILs. 
However, we did observe the development of a rash consistent 
with an acute autologous graft-vs.-host disease in roughly 20% 
of patients. This was mostly limited to the skin and resolved 
spontaneously. No long-term sequelae were evident in patients 
who received MILs.
A major objective of these studies was to determine the extent 
of immune responsiveness within the tumor microenvironment. 
For this reason, the immune monitoring was only performed on 
BM samples obtained at time points pre- and posttransplant. In 
addition to the direct correlation observed between the ex vivo 
expanded product and clinical outcomes, the MILs obtained 
from the patients up to 1 year posttransplant also demonstrated 
a direct correlation between the tumor specificity and the 
clinical response to therapy. MILs with the greatest antimyeloma 
specificity were observed in patients who achieved a CR. The CR 
patients also demonstrated an increase in CD8 cytotoxic activity 
as measured by both granzyme B and perforin production, an 
increase in IFNγ production, and a decrease in IL-6 production. 
One obstacle for many non-gene-modified T-cell studies has 
been the absence of persistence of ex vivo activated T-cells. We 
attempted to determine this in our study by vaccinating our 
patients the polyvalent pneumococcal vaccine (PCV) prior to 
harvesting the MILs and then reinfusing the MILs into a host 
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with a T-cell-depleted graft where the MILs constituted more 
than 95% of the adoptively transferred T cells. As such, it is fair 
to assume that the vast majority of PCV-specific MILs were those 
adoptive transferred. Our ability to detect PCV-specific MILs up 
to 1 year posttransplant, especially in patients who achieved a CR 
strongly, suggests their persistence.
Ongoing clinical studies are addressing approaches aimed at 
increasing the efficacy of MILs adoptive cell therapy. These have 
included the addition of a cellular allogeneic myeloma vaccine 
(myeloma-GVAX) as well as the use of the lenalidomide follow-
ing immune reconstitution. The former attempts to increase the 
precursor frequency of myeloma-specific MILs, and the latter 
attempts to maintain the activation state of the MILs.
Post-Allogeneic transplant MiLs
A major unmet need in allogeneic stem cell transplantation 
remains the difficulty of dealing with relapse disease following 
the transplant. The current standard approach is the use of 
donor lymphocyte infusions (DLI), which has a limited efficacy 
but is associated with a significant incidence of graft-vs.-host 
disease (GVHD) that can be in excess of 50% (27). The recent 
development at our center are allogeneic transplants with the 
use of posttransplant cyclophosphamide (PTCy), which has 
significantly reduced the incidence of GVHD and has enabled 
transplants to be performed across HLA barriers without 
significant increases in the morbidity or mortality compared to 
HLA-identical transplants (28). Because of the PTCy elimina-
tion of alloreactive T-cells, we hypothesized that MILs obtained 
from these patients posttransplant could be utilized therapeuti-
cally as a modified version of DLI with a better toxicity profile 
and heightened tumor specificity. The rationale is that the 
PTCy would have eliminated the alloreactive T-cells and the 
BM would possess the donor-derived tumor-specific T-cells. As 
such, we should be able to obtain MILs from these patients in 
the post-allogeneic transplant setting, activate, and expand these 
cells. The expectation is that the MILs would have heightened 
tumor specificity, effectively traffic to the BM, eradicate exist-
ing disease, and cause minimal, if any, GVHD. In preclinical 
experiments, the tumor specificity of MILs, following anti-CD3/
CD28 activation, was observed in all patients examined, and 
one patient in whom a tetramer existed for the HLA-A2+ PR-1 
peptide, the precursor frequency of MILs went from 1 to 17.8% 
following expansion (unpublished data). Considering the poly-
clonal expansion achieved with anti-CD3/CD28 stimulation, 
the theoretical ability to increase the antigenic frequency to 
numerous antigens by this percentage with minimal associated 
toxicity offers significant promise as an approach that should 
significantly improve the therapeutic outcomes for patients 
relapsing following an allogeneic BMT.
sOLiD tUMOrs
The positive prognostic value in terms of overall survival of TILs in 
many solid tumors points to a clear role of the immune system in 
regulating cancer growth (29–31). This has been further evidenced 
by the clinical benefits observed in many metastatic melanoma 
patients treated with TILs (32). However, a major limitation to such 
an approach is that not all patients have TILs that can be harvested, and 
the harvesting is a surgical procedure with all its limitations.
The presence of tumor-specific T-cells in the BM of patients 
with solid tumors opens up the prospect of utilizing MILs for 
therapeutic adoptive T-cell therapy in this setting, despite the 
presence of tumor within the BM. This approach has been exam-
ined in patients with metastatic breast cancer (33). In that study, 
16 HLA-A2+ patients had MILs cocultured with autologous DCs 
and an allogeneic breast cancer cell line, MCF7. An average of 
2 × 107 T-cells were infused without a lymphoablative preparative 
regimen. There was a direct correlation between the number of 
tumor-specific infused T-cells, the presence of a memory pheno-
type, and the absence of a Th2 phenotype with the overall response. 
Interestingly, patients with evidence of tumor-specific immunity 
in PBL showed a significantly longer median survival compared to 
non-responders (58.6 vs. 13.6 months; p = 0.009) (34).
cHiMeric ANtiGeN recePtOr-
MODiFieD t ceLLs
Chimeric antigen receptor (CAR) T-cells have demonstrated the 
ability to eradicate significant tumor burdens in patients with 
chronic lymphocytic leukemia (35) and acute lymphoblastic leu-
kemia (36, 37). While the response rates are impressively around 
70–90% in ALL with a 6-month event-free survival of 67%, the 
overall mechanisms of relapse are not completely understood. 
The development of antigen-escape variants are clearly observed 
in a fraction of the patients (38). One approach being developed 
to overcome this problem is to utilize an additional CAR, which 
in the case of ALL has been developed to target CD22 (39). An 
alternative approach could be to utilize a cell with an intrinsically 
broader antigenic specificity than that found on a PBL. MILs 
would appear to possess such properties and as such could poten-
tially serve as a better source of T-cells for CAR-based adoptive 
T-cell therapy.
cONcLUsiON
The BM represents a unique immunologic environment that 
serves both as a reservoir of memory T-cells and can effectively 
prime naive T-cells. This is, in large part, due to the efficient 
processing and presentation of antigens by resident APCs. The 
major benefit of this biology is that MILs possess many essential 
properties that make them ideal for adoptive T-cell therapy: they 
are enriched for TCM, they possess a broad antigenic specificity, 
effectively traffic to the BM upon reinfusion, and are capable of 
significant cytotoxicity. Furthermore, the presence of antigen-
specific T-cells in the BM in patients with certain viral infections, 
as well as solid tumors, potentially provides the rationale to utilize 
MILs for adoptive T-cell therapy.
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